Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T21:03:40.694Z.
Calculation as of: 2026-10-06T21:03:40.694Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 667dd3b64d3a271f66e92979ae52668ccbc7e2b5b2cdee7c8377401ac3ef4785
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$419.87M
EBITDA Yield
N/A
TTM Avg
6.82%
3Y Avg
6.82%
5Y Avg
6.82%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tectonic Therapeutic, Inc. (TECX) | $422.86M | N/A | N/A | N/A | N/A |
| Tilray Brands, Inc. (TLRY)vs › | $422.72M | 4.37% | 3.97% | 3.97% | 3.97% |
| NeoGenomics, Inc. (NEO)vs › | $424.10M | N/A | 1.44% | 5.28% | 7.05% |
| Prothena Corporation plc (PRTA)vs › | $419.87M | N/A | 6.82% | 6.82% | 6.82% |
| ARS Pharmaceuticals, Inc. (SPRY)vs › | $426.51M | N/A | N/A | N/A | N/A |
| Editas Medicine, Inc. (EDIT)vs › | $418.95M | N/A | N/A | N/A | N/A |
| Senseonics Holdings, Inc. (SENS)vs › | $416.27M | N/A | N/A | N/A | N/A |
| Rezolute, Inc. (RZLT)vs › | $415.98M | N/A | N/A | N/A | N/A |
| NeuroPace, Inc. (NPCE)vs › | $431.97M | N/A | N/A | N/A | N/A |
| MapLight Therapeutics, Inc. (MPLT)vs › | $411.21M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
